Sanofi weighs Mirati buy as KRAS cancer drug battle enters new phase

Mirati Therapeutics enjoyed a stock-price spike Thursday after rumors started swirling about a potential buyout by French drug giant Sanofi.

Sanofi has been evaluating a potential acquisition of Mirati, Bloomberg reports, citing people familiar with the matter.